抗 CBL 磁珠
02AB00100
CBL is a crucial regulator of cellular signaling pathways, primarily functioning as an E3 ubiquitin ligase that mediates the degradation of activated receptor tyrosine kinases (RTKs) through ubiquitination. This process is vital for maintaining cellular homeostasis and preventing aberrant signaling, which can lead to oncogenesis. Mutations or dysregulation of CBL have been implicated in various cancers, including acute myeloid leukemia, colorectal cancer, and breast cancer, where its loss of function contributes to sustained RTK signaling and tumor progression. Specifically, CBL mutations can result in the activation of oncogenic pathways, as seen in myeloproliferative neoplasms, where inactivated CBL mutants disrupt normal cellular processes and promote oncogenic transformations. Additionally, CBL's role in diseases like Noonan syndrome highlights its importance beyond cancer, indicating a broader impact on cellular signaling and development.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 宿主
- Mouse
- 靶点基因名
- CBL
- 基因别名
- CBL2; RNF55
- 蛋白别名
- Cbl proto-oncogene; CBL
- UniProt
- P22681
- 物种
- Human
- 应用
- IP
产品详情
- 靶点名称
- CBL
- 蛋白名称
- Cbl proto-oncogene
- 蛋白别名
- E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; RING-type E3 ubiquitin transferase CBL; Signal transduction protein CBL
- 靶点基因名
- CBL
- 基因别名
- CBL2; RNF55
- UniProt
- P22681
- 来源物种
- Homo sapiens (Human)
- 宿主物种
- Mouse
- 物种反应性
- Human
- 克隆性
- Monoclonal
- 亚型
- IgG1
- 配方
- Supplied as solution in phosphate buffered saline containing 0.1% BSA and 0.02% sodium azide
- 剂型
- Subject to solid-liquid separation upon standing; Mix thoroughly to ensure a consistent, homogeneous
免疫原核心序列
KPLPVPPTLRDLPPPPPPDRPYSVGAESRPQRRPLPCTPGDCPSRDKLPPVPSSRLGDSWLPRPIPKVPVSAPSSSDPWT
| 应用 | 推荐稀释比 | 备注 |
|---|---|---|
| IP | — | 50-100 μL/200 μg cell lysate |
背景介绍
CBL is a crucial regulator of cellular signaling pathways, primarily functioning as an E3 ubiquitin ligase that mediates the degradation of activated receptor tyrosine kinases (RTKs) through ubiquitination. This process is vital for maintaining cellular homeostasis and preventing aberrant signaling, which can lead to oncogenesis. Mutations or dysregulation of CBL have been implicated in various cancers, including acute myeloid leukemia, colorectal cancer, and breast cancer, where its loss of function contributes to sustained RTK signaling and tumor progression. Specifically, CBL mutations can result in the activation of oncogenic pathways, as seen in myeloproliferative neoplasms, where inactivated CBL mutants disrupt normal cellular processes and promote oncogenic transformations. Additionally, CBL's role in diseases like Noonan syndrome highlights its importance beyond cancer, indicating a broader impact on cellular signaling and development.